Role of Candida glabrata as nosocomial pathogen and its susceptibility to Fluconazole, Voriconazole, Caspofungin, Micafungin and Amphotericin B
Authors:
Open Access
- 15 August 2021
- journal article
- research article
- Published by Clinical Biotec S.L. in Bionatura
- Vol. 3 (3) , 2001-2008
Abstract
Candida has different types that could cause bloodstream infections. A total number of 150 samples were collected from candidemia patients and examined. The Candida spp. Species isolated from blood samples were analysed. These were identified by culturing the species using different media, namely the chromogenic agar test. Then, the virulence factors of all samples were tested. The Candida glabrata isolates were tested with six commercial antifungal drugs. C. glabrata 67 (44.6%), C. albicans 34 (22.6%), C. krusei 18 (12%), C. tropicalis 17 (11.3%), and C. parasilosis 14 (9.3%). the production of phospholipase ranged between 0.63-0.99 mm. It was found that 96% of the species showed phospholipase activity in aerobic conditions. The protease activities of Candida spp. Isolates were experimentally tested by area of inhibition around the colonies, where 59.3% had the double (++) protease activity, 31.4% with (+) grade, and 9.3% had (–) grade or clear zone around the colony. The hemolytic capacity ranged from 0.69-0.89 in the optimum aerobic environments. Finally, 38.33% of the isolated Candida spp. were positive and 61.67% negative for biofilm formation. Out of the total positive Candida spp. for biofilm formation, 21.73% were strong biofilm producers, and 78.27% were weak. Minimum fungicidal concentration (MFC) of Fluconazole for C. glabrata isolates was not appropriate (NA) due to the occurrence of low inhibition tested for species. Micafungin exhibited the lowest fungicidal activity against C. glabrata ranging from 0.03 - 0.125, while Fluconazole showed the highest.Keywords
This publication has 35 references indexed in Scilit:
- Inhibition of Growth of Highly Resistant Bacterial and Fungal Pathogens by a Natural ProductThe Open Microbiology Journal, 2011
- Invasive Candidiasis: An Overview from TaiwanJournal of the Formosan Medical Association, 2009
- Treatment-related risk factors for hospital mortality in Candida bloodstream infections*Critical Care Medicine, 2008
- Outwitting Multidrug Resistance to AntifungalsScience, 2008
- Efficacy of Chromogenic Candida Agar for isolation and presumptive identification of pathogenic yeast speciesClinical Microbiology and Infection, 2008
- The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity AnalysisClinical Infectious Diseases, 2005
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- Optimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative StudyJournal of Clinical Microbiology, 2002
- Performance of Candida ID, a New Chromogenic Medium for Presumptive Identification of Candida Species, in Comparison to CHROMagar CandidaJournal of Clinical Microbiology, 2001
- Antifungal Susceptibility Testing: Practical Aspects and Current ChallengesClinical Microbiology Reviews, 2001